Teva Pharmaceutical (TEVA) Gets a Buy from Barclays - Markets …

3 days ago · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

CouponFollow Extension

$25.00
OFF

Teva Pharmaceutical (TEVA) Gets A Buy From Barclays - Markets …

2 weeks from now

3 days ago · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$25.00
OFF

Teva Pharmaceutical (TEVA) Receives A Buy From Barclays

2 weeks from now

Oct 23, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $25.00. The company’s shares …

businessinsider.com

$25
OFF

Teva Price Target Raised To $25 From $22 At Barclays - Nasdaq

2 weeks from now

Oct 23, 2024 · TEVA. Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, …

nasdaq.com

26%
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · TEVA. 1.26%. Barclays has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

$24
OFF

Teva Pharmaceutical Analyst Ratings - Stock Analysis

2 weeks from now

A list of analyst ratings for Teva Pharmaceutical (TEVA) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. ... Strong Buy. Maintains. $24 → $26. …

stockanalysis.com

$25
OFF

Teva Price Target Raised To $25 From $22 At Barclays - Markets Insider

2 weeks from now

Oct 23, 2024 · Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV …

businessinsider.com

68%
OFF

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

2 weeks from now

2 days ago · Earnings for Teva Pharmaceutical Industries are expected to grow by 13.68% in the coming year, from $2.34 to $2.66 per share. Price to Earnings Ratio vs. the Market. The P/E …

marketbeat.com

$25.00
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · Barclays (LON: BARC) has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

$17.00
OFF

Barclays Sticks To Its Buy Rating For Teva Pharmaceutical (TEVA)

2 weeks from now

Feb 5, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $17.00.The company’s shares …

businessinsider.com

$60.00
OFF

Tarsus Pharmaceuticals (TARS) Gets A Buy From Barclays

2 weeks from now

1 day ago · Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares …

businessinsider.com

$10.00
OFF

Barclays Reaffirms Their Buy Rating On Amneal Pharmaceuticals …

2 weeks from now

3 days ago · Barclays analyst Balaji Prasad maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report) today and set a price target of $10.00. The company’s shares …

businessinsider.com

FAQs about Teva Pharmaceutical (TEVA) Gets a Buy from Barclays - Markets … Coupon?

Should you buy Teva Pharmaceutical (Teva)?

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. In a report released on October 16, UBS also maintained a Buy rating on the stock with a $26.00 price target. ...

Is Teva Pharmaceutical (Teva) overweight?

U.S.-listed shares of Teva Pharmaceutical ( NYSE: TEVA) are trading higher in the pre-market Tuesday after Barclays moved to upgrade the Israel-based generic drugmaker to Overweight from Equal Weight. The price target raised to $13 from $11 per share implies a premium of ~31% to the last close. ...

Where can I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? ...

How did Teva Pharmaceutical Industries' stock perform in 2024?

Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA stock has increased by 75.6% and is now trading at $18.33. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its quarterly earnings data on Wednesday, July, 31st. ...

Should you buy Prasad pharmaceutical (Teva)?

According to TipRanks, Prasad has an average return of 3.0% and a 46.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. ...

How much did Teva Pharmaceutical Industries earn in Q1?

The company earned $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 39.66% and a negative net margin of 2.73%. ...